| Ms Madeleine H Howell, MFT | |
|
9 Wichita Way, Ellsworth, ME 04605-1816 | |
| (207) 669-8287 | |
| (207) 669-8287 |
| Full Name | Ms Madeleine H Howell |
|---|---|
| Gender | Female |
| Speciality | Marriage & Family Therapist |
| Location | 9 Wichita Way, Ellsworth, Maine |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912067786 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 106H00000X | Marriage & Family Therapist | MF#3148 (Maine) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Madeleine H Howell, MFT 9 Wichita Way, Ellsworth, ME 04605-1816 Ph: (207) 669-8287 | Ms Madeleine H Howell, MFT 9 Wichita Way, Ellsworth, ME 04605-1816 Ph: (207) 669-8287 |
News Archive
Today, the U.S. Food and Drug Administration issued warning letters to 10 firms who manufacture and operate websites selling electronic nicotine delivery system (ENDS) products, specifically e-liquids, advising them that selling these products, which lack premarket authorization, is illegal, and therefore they cannot be sold or distributed in the U.S.
Prof. Lars Leksell (1907-1986), inventor of the radiosurgical instrument that bears his name and a faculty member of Karolinska University Hospital (Solna, Sweden), performed the world's first Gamma Knife® surgery at nearby Sophiahemmet Hospital, the location of the first Leksell Gamma Knife. Karolinska University Hospital recently acquired Elekta's fifth generation radiosurgery system, Leksell Gamma Knife® Perfexion™.
Birth defects in babies born infected with Zika virus remain a major health concern. Now, scientists suggest the possibility that some women in high-risk Zika regions may already be protected and not know it.
DNA Heritage has recently overcome patent claims held by a competitor which would have severely restricted the use of DNA testing and databases that allow families around the world to match and connect up through their DNA.
Genzyme Corporation (Nasdaq: GENZ) announced today that its supplemental New Drug Application for Clolar® (clofarabine) will be discussed Tuesday, September 1 at a public meeting of the FDA's Oncologic Drugs Advisory Committee in Silver Spring, Maryland. The panel is expected to consider the clinical trial results Genzyme submitted to support the approval and labeling of Clolar to treat older adult patients with acute myeloid leukemia (AML), the most common type of acute leukemia in adults.
› Verified 5 days ago
Ms. Charlotte Miles Young, M.S. Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 56 Church St, Ellsworth, ME 04605 Phone: 207-667-8358 |